- 5F-5,3-AB-PFUPPYCA
- AZ-037
- AMB-5F-P5FUPPYZ3CA
- 5F-AB-FUPPYCA
- N2-[1-(5-Fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carbonyl]-L-valinamide
- N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #43
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #109
Brandt, SD; Kavanagh, PV; Westphal, F; Dreiseitel, W; Dowling, G; Bowden, MJ; Williamson, JPB. Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233 Drug Test. Anal., 16 Aug 2020, 13 (1), 175-196. 2.6 MB. https://doi.org/10.1002/dta.2913 #5F-AB-FUPPYCA GC,MS,NMR
Andrews, R; Jorge, R; Christie, R; Gallegos, A. From JWH‐018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day Drug Test. Anal., 1 Apr 2023, 15 (4), 378–387. 1.2 MB. https://doi.org/10.1002/dta.3422 #5F-AB-FUPPYCA